1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This phase II single arm study is being done to determine if bavituximab could potentially
synergize with PD-1 inhibitor therapy to generate an effective anti-tumor immune response in
patients with recurrent/metastatic squamous cell head and neck cancer (HNSCC) who progressed
on a PD-1 inhibitor.